The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Oct. 17, 2012
|
2 min read
Sept. 21, 2012
|
2 min read
July 27, 2012
|
1 min read
July 5, 2012
|
2 min read
Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
June 20, 2012
|
5 min read
The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
May 25, 2012
|
2 min read
The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.
May 24, 2012
|
1 min read